Abstract
Immunotherapy for cancer patients is currently one of the most promising therapeutic approaches. Its treatment capabilities extend beyond immune checkpoint inhibitors and include cellular technologies and antitumor vaccines. The latter is the focus of the work by colleagues from the N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia. This communication presents a critical analysis of the results published in Voprosy Onkologii (Problems in Oncology) journal regarding the use of the CaTeVac vaccine in melanoma patients within the DENDRON-01 study.
References
Нехаева Т.Л., Ефремова Н.А., Новик А.В., et al. Применение аутологичной дендритно-клеточной вакцины CaTeVac у больных меланомой: заключительные результаты исследования DENDRON-01. Вопросы онкологии. 2025; 71(4).-DOI: https://doi.org/10.37469/0507-3758-2025-71-4-OF-2437.-URL: https://voprosyonkologii.ru/index.php/journal/article/view/4-25-The-Autologous. [Nekhaeva T.L., Efremova N.A., Novik A.V., et al. The use of the autologous CaTeVac dendritic cell vaccine in patients with melanoma: final results of the DENDRON-01 study. Voprosy Onkologii = Problems in Oncology. 2025; 71(4).-DOI: https://doi.org/10.37469/0507-3758-2025-71-4-OF-2437.-URL: https://voprosyonkologii.ru/index.php/journal/article/view/4-25-The-Autologous

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2026
